Product Description: HAMI 3379 is a potent and selective CysLT2 receptor antagonist. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation[1][2].
Applications: COVID-19-immunoregulation
Formula: C34H45NO8
References: [1]F Wunder, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409./[2]Q J Shi, et al. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience. 2015 Apr 16;291:53-69.
CAS Number: 1245653-57-9
Molecular Weight: 595.72
Compound Purity: 99.76
Research Area: Inflammation/Immunology; Cardiovascular Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Leukotriene Receptor
Deutsch
English
